Table 3.
Chemotherapy, antiemetic prophylaxis and CINV outcomes
| |
Breast cancer |
Carboplatin-treated lung cancer |
Cisplatin-treated lung cancer |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | Older 5-HT3RAs | Palonosetron | P* | All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | |
| N |
3,606 |
1,742 |
186 |
|
4,497 |
2,691 |
1,806 |
|
1,154 |
764 |
390 |
|
| CT tx days, mean (SD) |
4.2 (1.2) |
4.3 (1.3) |
4.2 (1.2) |
0.0297 |
6.1 (3.7) |
6.2 (3.6) |
6.1 (3.6) |
NS |
5.8 (4.3) |
6.3 (4.7) |
4.9 (3.2) |
<0.0001 |
| All antiemetic claims |
9.1 (5.1) |
9.9 (5.5) |
8.3 (4.6) |
<0.0001 |
10.2 (6.7) |
11.4 (7.2) |
8.5 (5.4) |
<0.0001 |
13.0 (8.0) |
15.3 (8.0) |
8.5 (5.6) |
<0.0001 |
| All 5-HT3 RA claims |
7.0 (3.9) |
7.9 (4.2) |
6.2 (3.4) |
<0.0001 |
9.2 (6.0) |
10.3 (6.4) |
7.7 (4.9) |
<0.0001 |
10.9 (6.9) |
13.1 (6.8) |
6.4 (4.4) |
<0.0001 |
| Days with hospital/ED associated CINV events |
0.1 (0.7) |
0.1 (0.9) |
0.1 (0.4) |
0.0052 |
0.3 (1.3) |
0.3 (1.4) |
0.2 (1.2) |
0.0004 |
0.6 (2.0) |
0.7 (2.1) |
0.6 (1.9) |
0.0499 |
| Pts with > =1 hospital/ED associated CINV events, N (%) | 161 (4.5) | 95 (5.5) | 66 (3.5) | 0.0055 | 516 (11.5) | 345 (12.8) | 171 (9.5) | 0.0005 | 230 (19.9) | 166 (21.7) | 64 (16.4) | 0.0324 |
CT: chemotherapy, Tx: treatment, ED: emergency department, pts: patients.
P values were based on t-tests, except for days and proportions of patients with hospital/ED associated CINV events, where the nonparametric Wilcoxon and Chi-square tests were used, respectively.